Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)

Historic Finished Goods for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q1 2025 value amounting to $7.3 million.

  • ARS Pharmaceuticals' Finished Goods changed N/A to $7.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.3 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2024, which is N/A changed from last year.
  • Per ARS Pharmaceuticals' latest filing, its Finished Goods stood at $7.3 million for Q1 2025.
  • In the past 5 years, ARS Pharmaceuticals' Finished Goods ranged from a high of $7.3 million in Q1 2025 and a low of $5.2 million during Q4 2024